Please access useful resources for the CKM Exchange Madrid meeting below.
Pre-read publications:
Nonsteroidal MRAs for Heart Failure With Preserved Ejection Fraction: Quantum Leap or Incremental Step?
Desai et al, 2026
Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure
Michos et al, 2026
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction
Vaduganathan et al, 2025
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Agarwal et al, 2022
Finerenone in persons with chronic kidney disease without diabetes
Heerspink et al, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)
Neuen et al, 2026
Finerenone in Type 1 Diabetes and Chronic Kidney Disease
Heerspink et al, 2026
Pre-read publications:
To prepare for this workshop, please consider the following key question:
Thinking about your own clinical practice, where do you see the greatest challenges in navigating different types of guidance, including international guidelines, expert consensus recommendations, and national or local guidance, and applying these in routine patient care?
Pre-read publications:
2026 ESC Guidelines for the Management of Heart Failure
Køber et al, 2026
KDIGO 2027 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD): Medications Management – Public Review Draft (October 2026)
KDIGO, 2026
To prepare for this workshop, please consider the following key question:
Thinking about the new indication for finerenone in HF with LVEF ≥40%, in which clinical situations would you feel confident initiating treatment, what factors contribute to this confidence, and where do you see areas of uncertainty or hesitation?
Pre-read publications:
Pre-read publications:
To prepare for this workshop, please consider the following key question:
Thinking about your own country and clinical practice, what are the biggest barriers to finerenone adoption in HF with LVEF ≥40%, and what practical solutions or existing resources could help overcome these challenges?